Barclays Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target decreased by Barclays from $923.00 to $917.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. Barclays‘s price objective points to a potential upside of 30.73% from the stock’s current price.

A number of other equities analysts also recently weighed in on REGN. TD Cowen boosted their target price on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a report on Thursday, April 23rd. Truist Financial lowered their target price on shares of Regeneron Pharmaceuticals from $801.00 to $796.00 and set a “buy” rating on the stock in a report on Thursday. Cantor Fitzgerald restated an “overweight” rating and set a $800.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, April 23rd. Guggenheim boosted their target price on shares of Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $826.59.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $701.42 on Thursday. The company’s fifty day simple moving average is $756.81 and its 200-day simple moving average is $735.17. The company has a quick ratio of 3.39, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. The firm has a market cap of $74.15 billion, a PE ratio of 17.09, a P/E/G ratio of 1.63 and a beta of 0.30. Regeneron Pharmaceuticals has a 12 month low of $476.49 and a 12 month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. The business had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm’s revenue for the quarter was up 19.0% on a year-over-year basis. During the same period in the previous year, the company earned $8.22 earnings per share. Equities research analysts expect that Regeneron Pharmaceuticals will post 35.98 EPS for the current fiscal year.

Insider Buying and Selling

In other news, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the transaction, the senior vice president owned 4,272 shares of the company’s stock, valued at approximately $3,325,837.44. This represents a 32.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the transaction, the director directly owned 1,703 shares of the company’s stock, valued at $1,330,604.99. This trade represents a 49.03% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 3,774 shares of company stock valued at $2,942,738 over the last quarter. 7.02% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. WPG Advisers LLC increased its stake in shares of Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 25 shares during the period. SHP Wealth Management bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $26,000. Salomon & Ludwin LLC acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $27,000. Titan Wealth CI Ltd acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $29,000. Finally, Board of the Pension Protection Fund bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $31,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported a stronger-than-expected Q1 (revenue up ~19%, EPS beat) and announced a $3 billion share buyback — fundamentals and the buyback are clear upside catalysts for shareholder value. Regeneron reports strong Q1 CY2026
• Positive Sentiment: Guggenheim raised its price target to $995 and retained a Buy — that implies sizable upside and supports sentiment among growth/value investors. Guggenheim raises REGN target to $995
• Neutral Sentiment: Zacks highlights REGN as a long-term value pick — supportive narrative for buy-and-hold investors but not an immediate price catalyst. Why Regeneron is a Top Value Stock
• Neutral Sentiment: Several banks trimmed price targets modestly (Barclays, Truist, Wells Fargo) but largely kept positive/market-weight ratings — suggests analysts revised models after Q1 details but remain constructive overall. Analyst PT changes after Q1
• Negative Sentiment: Royal Bank of Canada cut its target to $762 and moved to a “sector perform” stance — a more cautious view that likely weighed on intraday selling pressure. RBC lowers REGN target to $762
• Negative Sentiment: Coverage and model cuts followed the Q1 release despite the beat; investors focused on items such as a 10% drop in net income year-over-year (even as revenue rose), which may have trimmed near-term expectations. Regeneron Q1 2026 net income falls 10%
• Negative Sentiment: Market reaction: shares fell despite the beat — coverage (Seeking Alpha) points to investor disappointment or guidance/forward assumptions as the reason for the drop. That momentum explains today’s weaker price action. Regeneron drops despite Q1 beat

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.